Search Prime Grants

2335086

Cooperative Agreement

Overview

Grant Description
Sttr phase ii: dermatologist-level detection of suspicious pigmented skin lesions from high-resolution full-body images -this small business technology transfer (sttr) phase ii project includes early detection of skin cancers, resulting in better outcomes and a reduction in mortality and healthcare expenditures. Each year in the united states, nearly 5 million people are treated for skin cancer, with an annual cost estimated at $8.1 billion.

Annual productivity losses are estimated to cost an additional $4.5 billion. There is a considerable health disparity in the diagnosis of skin cancer within the u.s.; the average wait time to see a dermatologist is currently 32.3 days but it varies greatly by location. Early detection reduces disfigurement by reducing the size and extent of surgical removal and reducing the side effects that late-stage patients experience from systemic therapies.

Furthermore, the project increases the economic competitiveness of the u.s. This small business technology transfer (sttr) phase ii project is to productize a novel, pigmented, lesion analysis system for wide field-of-view images. The product will be built on a previously developed total body photography system and proof of concept lesion classification software as a medical device that was developed in phase i.

The dermatoscope-like resolution provides a solid foundation for a system that can automatically (without the involvement of a dermatologist) detect and classify various skin conditions in a clinical setting and/or a radiology center (similar to how mammograms are done). Skin cancers, including both melanomas and non-melanomas, are the most common types of cancer in the united states. Early-stage identification of suspicious pigmented lesions in primary care settings can lead to improved melanoma prognosis and a possible 20-fold reductions in treatment cost.

This technology provides the healthcare system with a highly sensitive, specific, and economical means of providing annual skin cancer screening to all at risk individuals. This award reflects nsf's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23516
Awarding / Funding Agency
Place of Performance
Potomac, Maryland 20854-1512 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the End Date has been extended from 02/28/26 to 08/31/26 and the total obligations have increased 22% from $996,367 to $1,211,573.
Lumo Imaging was awarded Cooperative Agreement 2335086 worth $1,211,573 from National Science Foundation in March 2024 with work to be completed primarily in Potomac Maryland United States. The grant has a duration of 2 years 5 months and was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships. The Cooperative Agreement was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase II Programs (SBIR/STTR Phase II).

SBIR Details

Research Type
STTR Phase II
Title
STTR Phase II: Dermatologist-level detection of suspicious pigmented skin lesions from high-resolution full-body images
Abstract
This Small Business Technology Transfer (STTR) Phase II project includes early detection of skin cancers, resulting in better outcomes and a reduction in mortality and healthcare expenditures. Each year in the United States, nearly 5 million people are treated for skin cancer, with an annual cost estimated at $8.1 billion. Annual productivity losses are estimated to cost an additional $4.5 billion. There is a considerable health disparity in the diagnosis of skin cancer within the U.S.; The average wait time to see a dermatologist is currently 32.3 days but it varies greatly by location. Early detection reduces disfigurement by reducing the size and extent of surgical removal and reducing the side effects that late-stage patients experience from systemic therapies. Furthermore, the project increases the economic competitiveness of the U.S. This Small Business Technology Transfer (STTR) Phase II project is to productize a novel, pigmented, lesion analysis system for wide field-of-view images. The product will be built on a previously developed total body photography system and proof of concept lesion classification software as a medical device that was developed in Phase I. The dermatoscope-like resolution provides a solid foundation for a system that can automatically (without the involvement of a dermatologist) detect and classify various skin conditions in a clinical setting and/or a radiology center (similar to how mammograms are done). Skin cancers, including both melanomas and non-melanomas, are the most common types of cancer in the United States. Early-stage identification of suspicious pigmented lesions in primary care settings can lead to improved melanoma prognosis and a possible 20-fold reductions in treatment cost. This technology provides the healthcare system with a highly sensitive, specific, and economical means of providing annual skin cancer screening to all at risk individuals. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 23-516

Status
(Ongoing)

Last Modified 9/10/25

Period of Performance
3/1/24
Start Date
8/31/26
End Date
65.0% Complete

Funding Split
$1.2M
Federal Obligation
$0.0
Non-Federal Obligation
$1.2M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to 2335086

Transaction History

Modifications to 2335086

Additional Detail

Award ID FAIN
2335086
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
CPZMDJJ5B9Y5
Awardee CAGE
8HRN9
Performance District
MD-08
Senators
Benjamin Cardin
Chris Van Hollen
Modified: 9/10/25